Translational high-dimesional drug interaction discovery and validation using health record databases and pharmacokinetics models

Indiana University-Purdue University Indianapolis (IUPUI)Polypharmacy leads to increased risk of drug-drug interactions (DDI’s). In this dissertation, we create a database for quantifying fraction of metabolism (fm) of CYP450 isozymes for FDA approved drugs. A reproducible data collection protocol was developed to extract key information from publicly available in vitro selective CYP enzyme inhibition studies. The fm was then estimated from the curated data. Then, proposed a random control selection approach for nested case-control design for electronical health records (HER) and electronical medical records (EMR) databases. By relaxing the matching by case’s index time restriction, random control dramatically reduces the computational burden compared with traditional control selection approaches. Using the Observational Medical Outcomes Partnership gold standard and an EMR database, random control is demonstrated to have better performances as well. Finally, combining epidemiological studies and pharmacokinetic modeling with fm database, we detected and evaluated high-dimensional drug-drug interactions among thirty high frequency drugs. Multi-drug combinations that increased risk of myopathy were identified in the FAERS and EMR databases by a mixture drug-count response model (MDCM) model. Twenty-eight 3-way and 43 4-way DDI’s increased ratio of area under plasma concentration–time curve (AUCR) >2-fold and had significant myopathy risk in both databases. The predicted AUCR of omeprazole in the presence of fluconazole and clonidine was 9.35; and increased risk of myopathy was 6.41 (LFDR = 0.002) in FAERS and 18.46 (LFDR = 0.005) in EMR. We demonstrate that combining health record informatics and pharmacokinetic modeling is a powerful translational approach to detect high-dimensional DDI’s.2 year

Adverse Drug Event Detection, Causality Inference, Patient Communication and Translational Research

Adverse drug events (ADEs) are injuries resulting from a medical intervention related to a drug. ADEs are responsible for nearly 20% of all the adverse events that occur in hospitalized patients. ADEs have been shown to increase the cost of health care and the length of stays in hospital. Therefore, detecting and preventing ADEs for pharmacovigilance is an important task that can improve the quality of health care and reduce the cost in a hospital setting. In this dissertation, we focus on the development of ADEtector, a system that identifies ADEs and medication information from electronic medical records and the FDA Adverse Event Reporting System reports. The ADEtector system employs novel natural language processing approaches for ADE detection and provides a user interface to display ADE information. The ADEtector employs machine learning techniques to automatically processes the narrative text and identify the adverse event (AE) and medication entities that appear in that narrative text. The system will analyze the entities recognized to infer the causal relation that exists between AEs and medications by automating the elements of Naranjo score using knowledge and rule based approaches. The Naranjo Adverse Drug Reaction Probability Scale is a validated tool for finding the causality of a drug induced adverse event or ADE. The scale calculates the likelihood of an adverse event related to drugs based on a list of weighted questions. The ADEtector also presents the user with evidence for ADEs by extracting figures that contain ADE related information from biomedical literature. A brief summary is generated for each of the figures that are extracted to help users better comprehend the figure. This will further enhance the user experience in understanding the ADE information better. The ADEtector also helps patients better understand the narrative text by recognizing complex medical jargon and abbreviations that appear in the text and providing definitions and explanations for them from external knowledge resources. This system could help clinicians and researchers in discovering novel ADEs and drug relations and also hypothesize new research questions within the ADE domain

Analyzing adverse drug reaction using statistical and machine learning methods: A systematic review

Background: Adverse drug reactions (ADRs) are unintended negative drug-induced responses. Determining the association between drugs and ADRs is crucial, and several methods have been proposed to demonstrate this association. This systematic review aimed to examine the analytical tools by considering original articles that utilized statistical and machine learning methods for detecting ADRs. Methods: A systematic literature review was conducted based on articles published between 2015 and 2020. The keywords used were statistical, machine learning, and deep learning methods for detecting ADR signals. The study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) guidelines. Results: We reviewed 72 articles, of which 51 and 21 addressed statistical and machine learning methods, respectively. Electronic medical record (EMR) data were exclusively analyzed using the regression method. For FDA Adverse Event Reporting System (FAERS) data, components of the disproportionality method were preferable. DrugBank was the most used database for machine learning. Other methods accounted for the highest and supervised methods accounted for the second highest. Conclusions: Using the 72 main articles, this review provides guidelines on which databases are frequently utilized and which analysis methods can be connected. For statistical analysis, >90% of the cases were analyzed by disproportionate or regression analysis with each spontaneous reporting system (SRS) data or electronic medical record (EMR) data; for machine learning research, however, there was a strong tendency to analyze various data combinations. Only half of the DrugBank database was occupied, and the k-nearest neighbor method accounted for the greatest proportion.ope

Automatically Recognizing Medication and Adverse Event Information From Food and Drug Administration\u27s Adverse Event Reporting System Narratives

BACKGROUND: The Food and Drug Administration\u27s (FDA) Adverse Event Reporting System (FAERS) is a repository of spontaneously-reported adverse drug events (ADEs) for FDA-approved prescription drugs. FAERS reports include both structured reports and unstructured narratives. The narratives often include essential information for evaluation of the severity, causality, and description of ADEs that are not present in the structured data. The timely identification of unknown toxicities of prescription drugs is an important, unsolved problem. OBJECTIVE: The objective of this study was to develop an annotated corpus of FAERS narratives and biomedical named entity tagger to automatically identify ADE related information in the FAERS narratives. METHODS: We developed an annotation guideline and annotate medication information and adverse event related entities on 122 FAERS narratives comprising approximately 23,000 word tokens. A named entity tagger using supervised machine learning approaches was built for detecting medication information and adverse event entities using various categories of features. RESULTS: The annotated corpus had an agreement of over .9 Cohen\u27s kappa for medication and adverse event entities. The best performing tagger achieves an overall performance of 0.73 F1 score for detection of medication, adverse event and other named entities. C ONCLUSIONS: In this study, we developed an annotated corpus of FAERS narratives and machine learning based models for automatically extracting medication and adverse event information from the FAERS narratives. Our study is an important step towards enriching the FAERS data for postmarketing pharmacovigilance

Artificial Intelligence in Oncology Drug Discovery and Development

There exists a profound conflict at the heart of oncology drug development. The efficiency of the drug development process is falling, leading to higher costs per approved drug, at the same time personalised medicine is limiting the target market of each new medicine. Even as the global economic burden of cancer increases, the current paradigm in drug development is unsustainable. In this book, we discuss the development of techniques in machine learning for improving the efficiency of oncology drug development and delivering cost-effective precision treatment. We consider how to structure data for drug repurposing and target identification, how to improve clinical trials and how patients may view artificial intelligence

Effect of Root Cause Analysis on Pre-Licensure, Senior-Level Nursing Students’ Safe Medication Administration Practices

Aim: The aim of this study was to examine if student nurse participation in root cause analysis has the potential to reduce harm to patients from medication errors by increasing student nurse sensitivity to signal and responder bias. Background: Schools of nursing have traditionally relied on strategies that focus on individual characteristics and responsibility to prevent harm to patients. The modern patient safety movement encourages utilization of systems theory strategies like Root Cause Analysis (RCA). The Patient Risk Detection Theory (Despins, Scott-Cawiezell, & Rouder, 2010) supports the use of nurse training to reduce harm to patients. Method. Descriptive and inferential analyses of the demographic and major study variables were conducted. Validity and reliability assessments for the instruments were performed. The Safe Administration of Medications-Revised Scale (Bravo, 2014) was used to measure sensitivity to signal. The Safety Attitudes Questionnaire (SAQ; Sexton et al., 2006) was used to assess responder bias; this was the first use of this instrument with nursing students. Results: The sample consisted of 125 senior-level nursing students from three universities in the southeastern United States. The SAQ was found to be a valid and reliable test of safety attitudes in nursing students. Further support for the validity and reliability of the SAM-R was provided. A significant difference in safety climate between schools was observed. There were no differences detected between the variables. Conclusion: The results of this study provide support for the use of the SAQ and the SAM-R to further test the PRDT, and to explore methods to improve nursing student ability to administer medications safely

Electronic Medical Records and Machine Learning in Approaches to Drug Development

Electronic medical records (EMRs) were primarily introduced as a digital health tool in hospitals to improve patient care, but over the past decade, research works have implemented EMR data in clinical trials and omics studies to increase translational potential in drug development. EMRs could help discover phenotype-genotype associations, enhance clinical trial protocols, automate adverse drug event detection and prevention, and accelerate precision medicine research. Although feasible, data mining in EMRs still faces challenges. Existing machine learning tools may help overcome these bottlenecks in EMR mining to unlock new approaches in drug development. This chapter will explore the role of EMRs in drug development while evaluating the viability and bottlenecks of their uses in data mining. This will include discussions on EMR usage in drug development while highlighting successful outcomes in oncology and exploring ML tools to complement and enhance EMR as a widely accepted drug-research source, a section on current clinical applications of EMRs, and a conclusion to summarize and imagine what a future drug research pipeline from EMR to patient treatment may look like

Developing Predictive Models for Risk of Postoperative Complications and Hemodynamic Instability in Patients Undergoing Surgery

Patients undergoing high-risk surgeries are often at higher risk of developing hemodynamic instability during surgery resulting in poor postoperative outcomes. This is usually associated with significantly increased postoperative morbidity and mortality, which therefore makes the early identification of these critical events and those patients at risk of postoperative complications crucial. With these motivations in mind, we first created a large deidentified research dataset of surgical case medical records from University of California, Irvine Medical Center (UCIMC) matched with physiological waveforms as well as intermittent vital sign values, lab values, and ventilator settings. To our knowledge, such a dataset does not currently exist for the intraoperative environment. We hope that creating a such a dataset will allow for advances in machine learning for intraoperative care. Using medical data from UCLA, we have developed deep neural network models to classify the risks of postoperative mortality, acute kidney injury, and reintubation utilizing readily available intraoperative information. Our risk scores were compared to currently commonly used risk indices ASA and Surgical Apgar as well as logistic regression. While the deep neural network models performed better than the risk scores and logistic regression, clinicians require additional information to assess what led to increased risk of complications. To address this, we also assessed the use of generalized additive neural networks (GANNs) to create a graphical look at how different features contributed to the risk of in hospital mortality. Finally, we were also interested in predicting critical intraoperative events to allow for time for the clinician to avoid such events. We focused on intraoperative hypotension as it is easier to define and has been shown to lead to increased risk of acute kidney injury, stroke, and myocardial injury. For the hypotension prediction models, we looked at the arterial pressure waveform and EMR data as inputs. Overall, these aims address a gap in current clinical decision guidance and support to reduce adverse events during surgery as well complications after

Cybersecurity Vulnerabilities in Medical Devices: A Complex Environment and Multifaceted Problem

The increased connectivity to existing computer networks has exposed medical devices to cybersecurity vulnerabilities from which they were previously shielded. For the prevention of cybersecurity incidents, it is important to recognize the complexity of the operational environment as well as to catalog the technical vulnerabilities. Cybersecurity protection is not just a technical issue; it is a richer and more intricate problem to solve. A review of the factors that contribute to such a potentially insecure environment, together with the identification of the vulnerabilities, is important for understanding why these vulnerabilities persist and what the solution space should look like. This multifaceted problem must be viewed from a systemic perspective if adequate protection is to be put in place and patient safety concerns addressed. This requires technical controls, governance, resilience measures, consolidated reporting, context expertise, regulation, and standards. It is evident that a coordinated, proactive approach to address this complex challenge is essential. In the interim, patient safety is under threat